Pheochromocytomas/paragangliomas are characterized by a unique molecular landscape
that allows their assignment to clusters based on underlying genetic alterations. With around …

Phaeochromocytoma and paraganglioma (PPGL) are chromaffin cell tumours that require
timely diagnosis because of their potentially serious cardiovascular and sometimes life …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase
subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck …

Paragangliomas are neuroendocrine tumors that derive from paraganglia of the autonomic
nervous system, with the majority of parasympathetic paragangliomas arising in the head …

Abstract Context Pheochromocytomas and paragangliomas (PPGLs) are believed to harbor
malignant potential; about 10% to 15% of pheochromocytomas and up to 50% of abdominal …

Purpose In this study, we aim to evaluate the efficacy and safety of 225 AC-DOTATATE
targeted alpha therapy in advanced-stage paragangliomas (PGLs). Methods Nine (6 males …

Targeted radionuclide therapies (TRT) using 131I-metaiodobenzylguanidine (131I-MIBG)
and peptide receptor radionuclide therapy (177Lu or 90Y) represent several of the …

Background Peptide receptor radionuclide therapy (PRRT) is one of the most promising
therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain …

Opinion statement The incidence of metastatic pheochromocytoma (PHEO) and
paraganglioma (PGL) may occur in as many as 35% of patients particularly with PGL and …